Cargando…
The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1
Herpes simplex virus type 1 (HSV-1) is the only FDA- and EMA- approved oncolytic virus, and accordingly, many potential oncolytic HSVs (oHSV) are in clinical development. The utilized oHSV parental strains are, however, mostly based on laboratory reference strains, which may possess a compromised cy...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230972/ https://www.ncbi.nlm.nih.gov/pubmed/35746761 http://dx.doi.org/10.3390/v14061290 |
_version_ | 1784735213159448576 |
---|---|
author | Kalke, Kiira Orpana, Julius Lasanen, Tuomas Esparta, Olaya Lund, Liisa M. Frejborg, Fanny Vuorinen, Tytti Paavilainen, Henrik Hukkanen, Veijo |
author_facet | Kalke, Kiira Orpana, Julius Lasanen, Tuomas Esparta, Olaya Lund, Liisa M. Frejborg, Fanny Vuorinen, Tytti Paavilainen, Henrik Hukkanen, Veijo |
author_sort | Kalke, Kiira |
collection | PubMed |
description | Herpes simplex virus type 1 (HSV-1) is the only FDA- and EMA- approved oncolytic virus, and accordingly, many potential oncolytic HSVs (oHSV) are in clinical development. The utilized oHSV parental strains are, however, mostly based on laboratory reference strains, which may possess a compromised cytolytic capacity in contrast to circulating strains of HSV-1. Here, we assess the phenotype of thirty-six circulating HSV-1 strains from Finland to uncover their potential as oHSV backbones. First, we determined their capacity for cell-to-cell versus extracellular spread, to find strains with replication profiles favorable for each application. Second, to unfold the differences, we studied the genetic diversity of two relevant viral glycoproteins (gB/UL27, gI/US7). Third, we examined the oncolytic potential of the strains in cells representing glioma, lymphoma, and colorectal adenocarcinoma. Our results suggest that the phenotype of a circulating isolate, including the oncolytic potential, is highly related to the host cell type. Nevertheless, we identified isolates with increased oncolytic potential in comparison with the reference viruses across many or all of the studied cancer cell types. Our research emphasizes the need for careful selection of the backbone virus in early vector design, and it highlights the potential of clinical isolates as backbones in oHSV development. |
format | Online Article Text |
id | pubmed-9230972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92309722022-06-25 The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1 Kalke, Kiira Orpana, Julius Lasanen, Tuomas Esparta, Olaya Lund, Liisa M. Frejborg, Fanny Vuorinen, Tytti Paavilainen, Henrik Hukkanen, Veijo Viruses Article Herpes simplex virus type 1 (HSV-1) is the only FDA- and EMA- approved oncolytic virus, and accordingly, many potential oncolytic HSVs (oHSV) are in clinical development. The utilized oHSV parental strains are, however, mostly based on laboratory reference strains, which may possess a compromised cytolytic capacity in contrast to circulating strains of HSV-1. Here, we assess the phenotype of thirty-six circulating HSV-1 strains from Finland to uncover their potential as oHSV backbones. First, we determined their capacity for cell-to-cell versus extracellular spread, to find strains with replication profiles favorable for each application. Second, to unfold the differences, we studied the genetic diversity of two relevant viral glycoproteins (gB/UL27, gI/US7). Third, we examined the oncolytic potential of the strains in cells representing glioma, lymphoma, and colorectal adenocarcinoma. Our results suggest that the phenotype of a circulating isolate, including the oncolytic potential, is highly related to the host cell type. Nevertheless, we identified isolates with increased oncolytic potential in comparison with the reference viruses across many or all of the studied cancer cell types. Our research emphasizes the need for careful selection of the backbone virus in early vector design, and it highlights the potential of clinical isolates as backbones in oHSV development. MDPI 2022-06-13 /pmc/articles/PMC9230972/ /pubmed/35746761 http://dx.doi.org/10.3390/v14061290 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kalke, Kiira Orpana, Julius Lasanen, Tuomas Esparta, Olaya Lund, Liisa M. Frejborg, Fanny Vuorinen, Tytti Paavilainen, Henrik Hukkanen, Veijo The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1 |
title | The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1 |
title_full | The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1 |
title_fullStr | The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1 |
title_full_unstemmed | The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1 |
title_short | The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1 |
title_sort | in vitro replication, spread, and oncolytic potential of finnish circulating strains of herpes simplex virus type 1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230972/ https://www.ncbi.nlm.nih.gov/pubmed/35746761 http://dx.doi.org/10.3390/v14061290 |
work_keys_str_mv | AT kalkekiira theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT orpanajulius theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT lasanentuomas theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT espartaolaya theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT lundliisam theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT frejborgfanny theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT vuorinentytti theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT paavilainenhenrik theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT hukkanenveijo theinvitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT kalkekiira invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT orpanajulius invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT lasanentuomas invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT espartaolaya invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT lundliisam invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT frejborgfanny invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT vuorinentytti invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT paavilainenhenrik invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 AT hukkanenveijo invitroreplicationspreadandoncolyticpotentialoffinnishcirculatingstrainsofherpessimplexvirustype1 |